

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1-13 (cancelled)

Claim 14. (currently amended) A recombinant antibody ~~against~~ that binds human-TNF α or a fragment of said antibody, comprising an H Heavy chain polypeptide, ~~or its fragment~~, which has at least ~~one of~~ the following amino acid sequences:

- a) the amino acid sequence represented by SEQ ID NO:1 as CDR-H1;
- b) the amino acid sequence represented by SEQ ID NO:2 as CDR-H2; and
- c) the amino acid sequence represented by SEQ ID NO:3 as CDR-H3;

and an L Light chain polypeptide, ~~or its fragment~~, which has at least ~~one of~~ the following amino acid sequences:

- d) the amino acid sequence represented by SEQ ID NO:4 as CDR-L1;
- e) the amino acid sequence represented by SEQ ID NO:5 as CDR-L2; and
- f) the amino acid sequence represented by SEQ ID NO:6 as CDR-L3.

Claim 15. (currently amended) A recombinant antibody ~~against~~ that binds human TNF α or a fragment of said antibody as claimed in claim 14, which contains the H Heavy chain variable region of an antibody ~~against~~ that binds human TNF α comprising the amino acid sequence represented by SEQ ID NO:7 ~~or an amino acid sequence derived from said amino acid sequence by deletion, addition or substitution~~

~~of one to several amino acids in a region other than the amino acid sequences represented by SEQ ID NOS:1 to 3, or its fragment.~~

Claim 16. (currently amended) A recombinant antibody ~~against that binds~~ human TNF α or a fragment of said antibody as claimed in claim 14, which contains the ~~L~~ Light chain variable region of an antibody ~~against that binds~~ human TNF α comprising the amino acid sequence represented by SEQ ID NO:8 ~~or an amino acid sequence derived from said amino acid sequence by deletion, addition or substitution of one to several amino acids in a region other than the amino acid sequences represented by SEQ ID NOS:4 to 6, or its fragment.~~

Claim 17. (currently amended) A pharmaceutical composition comprising the antibody as claimed in claim 14 or its a fragment of said antibody together with a pharmaceutically acceptable carrier.

Claims 18-23. (cancelled)